The results of our cell cycle assay demonstrate that while the KRAS WT CRC cells show no significant differences in the number of G1, S, or G2 phase cells (p > 0.05), after 60 h of 10 μM PRMT5 inhibitor treatment, the KRAS mutant CRC cells showed a significant 7.3% (p < 0.05) increase in G2 phase cells, as well as a 5.0% (p < 0.05) decrease in S phase cells. This evidence concerns the gene KRAS and colorectal carcinoma.